XOMA (NASDAQ:XOMA) Raised to Hold at StockNews.com

XOMA (NASDAQ:XOMA) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

Separately, HC Wainwright reiterated a “buy” rating and issued a $104.00 target price on shares of XOMA in a report on Wednesday.

XOMA Trading Down 0.9 %

Shares of NASDAQ:XOMA traded down $0.18 during mid-day trading on Friday, reaching $20.88. 81,363 shares of the company’s stock were exchanged, compared to its average volume of 26,540. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. XOMA has a twelve month low of $19.92 and a twelve month high of $35.00. The firm has a market capitalization of $250.12 million, a price-to-earnings ratio of -6.00 and a beta of 1.00. The business’s fifty day moving average price is $24.37 and its 200-day moving average price is $27.14.

XOMA (NASDAQ:XOMA) last announced its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. On average, research analysts predict that XOMA will post -1.41 EPS for the current fiscal year.

Insider Activity at XOMA

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.20% of the stock is owned by company insiders.

Institutional Trading of XOMA

Several hedge funds have recently modified their holdings of the stock. Woodline Partners LP boosted its stake in XOMA by 63.9% during the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after acquiring an additional 60,927 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of XOMA by 238.9% during the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock valued at $318,000 after purchasing an additional 8,522 shares during the period. Barclays PLC boosted its position in shares of XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of XOMA in the 4th quarter valued at about $206,000. Finally, Renaissance Technologies LLC grew its stake in shares of XOMA by 89.8% in the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 7,619 shares during the period. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.